%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
74 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-01-05T12:02:46Z
2024-03-19T02:48:50-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-19T02:48:50-07:00
application/pdf
Heather
2003-480.feb
uuid:b6de1ed9-1dd1-11b2-0a00-e609275dc400
uuid:b6de1edb-1dd1-11b2-0a00-810000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
84 0 obj
[88 0 R]
endobj
85 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:2)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(392)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.00011 Tc 0.1431 Tw 10 0 0 10 54 713.1616 Tm
(the published criteria are clearly noted, lest they result in)Tj
0.0927 Tw 0 -1.2 TD
(inability to interpret and compare the reported data. It is a)Tj
0.0199 Tc 0.5294 Tw T*
(requirement, for example, for classification in the)Tj
0.00729 Tc 0.3676 Tw T*
[(polyarthritis rheumatoid positive category)64.7 (, that RF be)]TJ
-0.00011 Tc 0.1664 Tw T*
[(present on 2 occasions at least 3 months apart. )17.7 (This was)]TJ
-0.0166 Tw T*
[(intended to make certain the unrelated RF positivity)64.9 (, such as)]TJ
0.21671 Tw T*
(that which might follow an infection, not be allowed to)Tj
0.15829 Tw T*
(obscure what was felt to be significant persistent RF test)Tj
0.12939 Tw T*
[(positivity)64.8 (. )17.7 (This may be contrary to usual clinical practice,)]TJ
0.08459 Tw T*
(and has therefore been an impediment to the easy applica-)Tj
0.1425 Tw T*
[(tion of the criteria. )54.8 (Although RF testing would be ideally)]TJ
0.00349 Tw T*
(performed during the first 6 months of disease, this may not)Tj
0.0648 Tw T*
(always be possible, and test results obtained at a later time)Tj
0.1109 Tw T*
[(should then be used. )17.7 (These requirements should be evalu-)]TJ
0.1153 Tw T*
(ated; the results of such an evaluation may well influence)Tj
0.104 Tw T*
[(the criteria. )17.7 (The ILAR committee has concluded that until)]TJ
0.15041 Tw T*
(such data are forthcoming, in keeping with the principles)Tj
0.1573 Tw T*
(adopted by the committee, the requirement for 2 positive)Tj
0.02499 Tw T*
(tests for RF will be retained in the present revision.)Tj
0.3098 Tw 1.2 -1.2 Td
(It is anticipated that the proposed classification will)Tj
0.07651 Tw -1.2 -1.2 Td
[(under)17.7 (go further revision in order to correct anomalies, and)]TJ
0.2057 Tw T*
(in response to new information. Such changes would be)Tj
-0.0334 Tw T*
(incorporated if they resulted in a demonstrable and objective)Tj
0.0011 Tw T*
(improvement in homogeneity of the categories in the classi-)Tj
0.353 Tw T*
[(fication. )17.7 (The ILAR classification has proved useful in)]TJ
0.25349 Tw T*
[(sparking controversy)64.8 (, questions and international debate,)]TJ
0.1113 Tw T*
[(and research about JIA. )17.7 (The prospective gathering of new)]TJ
0.0349 Tw T*
(clinical information has been stimulated and will lead to an)Tj
0.02499 Tw T*
(improved understanding of these diseases.)Tj
/T1_3 1 Tf
0 -2.4 TD
(Ross E. Petty)Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.4 (, )]TJ
0.0249 Tw 6 0 0 6 116.1197 353.1616 Tm
(MD, PhD,)Tj
-0.00011 Tc 8 0 0 8 54 343.1616 Tm
[(Division of Rheumatology)64.8 (, Department of Pediatrics, University of)]TJ
0 -1.25 TD
[(British Columbia, )17.7 (V)110.8 (ancouver)39.7 (, BC, Canada;)]TJ
/T1_3 1 Tf
10 0 0 10 54 321.1616 Tm
[(T)91.7 (aunton R. Southwood)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 9.8759 0 Td
(, )Tj
0.0249 Tw 6 0 0 6 158.0093 321.1615 Tm
[(BM, BS, FRCP)110.8 (,)]TJ
-0.00011 Tc 8 0 0 8 54 311.1616 Tm
[(Department of Rheumatology)64.8 (, University of Birmingham, Birmingham,)]TJ
T*
(United Kingdom;)Tj
/T1_3 1 Tf
10 0 0 10 54 289.1616 Tm
(Prudence Manners)Tj
/T1_2 1 Tf
0 Tc 0 Tw (, )Tj
-0.00011 Tc 6 0 0 6 140.8623 289.1616 Tm
(MD,)Tj
0.02499 Tw 8 0 0 8 54 279.1616 Tm
[(School of Paediatrics and Child Health, University of )17.7 (W)79.9 (estern )54.8 (Australia,)]TJ
-0.0002 Tc -0.02969 Tw T*
(Perth, Australia;)Tj
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 10 0 0 10 54 257.1616 Tm
(John Baum)Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.5 (, )]TJ
-0.00011 Tc 6 0 0 6 108.6748 257.1616 Tm
(MD,)Tj
0.02499 Tw 8 0 0 8 54 247.1616 Tm
[(Department of Pediatrics, University of Rochester)39.7 (, Rochester)39.7 (, New )36.8 (Y)99.8 (ork,)]TJ
0 Tw T*
(USA;)Tj
/T1_3 1 Tf
0.02499 Tw 10 0 0 10 54 225.1616 Tm
(David N. Glass)Tj
/T1_2 1 Tf
0 Tc 0 Tw 6.4111 0 Td
(, )Tj
-0.00011 Tc 6 0 0 6 123.3609 225.1616 Tm
(MD,)Tj
0.02499 Tw 8 0 0 8 54 215.1616 Tm
[(Division of Rheumatology)64.8 (, Department of Pediatrics, Cincinnati)]TJ
T*
[(Children\325)54.8 (s Hospital Medical Center)39.7 (, Cincinnati, Ohio, USA;)]TJ
/T1_3 1 Tf
10 0 0 10 54 193.1616 Tm
(Jose Goldenberg)Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.3 (, )]TJ
0.0249 Tw 6 0 0 6 130.877 193.1616 Tm
(MD, PhD,)Tj
-0.00011 Tc 8 0 0 8 54 183.1616 Tm
[(Department of Rheumatology)64.8 (, Escola Paulista Medicina, Sao Paulo,)]TJ
-0.0002 Tc 0 Tw T*
(Brazil;)Tj
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 10 0 0 10 54 161.1616 Tm
(Xiaohu He)Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.3 (, )]TJ
-0.00011 Tc 6 0 0 6 105.3325 161.1616 Tm
(MD,)Tj
0.02499 Tw 8 0 0 8 54 151.1616 Tm
[(Department of Rheumatology)64.8 (, Beijing Children\325)54.8 (s Hospital, Beijing,)]TJ
0 Tw T*
(China;)Tj
/T1_3 1 Tf
0.02499 Tw 10 0 0 10 318 713.1616 Tm
(Jose Maldonado-Cocco)Tj
/T1_2 1 Tf
0 Tc 0 Tw 9.9395 0 Td
(, )Tj
-0.00011 Tc 6 0 0 6 422.6455 713.1616 Tm
(MD,)Tj
0.02499 Tw 8 0 0 8 318 703.1616 Tm
[(Department of Rheumatology)64.8 (, University of Buenos )54.8 (Aires, Buenos )54.8 (Aires,)]TJ
0 Tw T*
[(Ar)17.7 (gentina;)]TJ
/T1_3 1 Tf
10 0 0 10 318 681.1616 Tm
[(Javier)-257.3 (Or)17.7 (ozco-Alcala)]TJ
/T1_2 1 Tf
0 Tc [0.1 (, )]TJ
-0.00011 Tc 6 0 0 6 413.9346 681.1616 Tm
(MD,)Tj
0.02499 Tw 8 0 0 8 318 671.1616 Tm
[(Department of Rheumatology)64.8 (, Hospital Civil, Guadalajara, Mexico;)]TJ
/T1_3 1 Tf
10 0 0 10 318 659.1616 Tm
(Anne-Marie Prieur)Tj
/T1_2 1 Tf
0 Tc 0 Tw [0.4 (, )]TJ
-0.00011 Tc 6 0 0 6 405.9585 659.1616 Tm
(MD,)Tj
0.02499 Tw 8 0 0 8 318 651.1616 Tm
(Pediatric Immunohematology and Rheumatology Unit, H\231pital Necker)Tj
0 -1 TD
(Enfants Malades, Paris, France;)Tj
/T1_3 1 Tf
10 0 0 10 318 631.1616 Tm
[(Maria E. Suar)17.7 (ez-Almazor)]TJ
/T1_2 1 Tf
0 Tc 0 Tw [-0.2 (, )]TJ
-0.00011 Tc 0.02499 Tw 6 0 0 6 434.3604 631.1616 Tm
(MD, PhD,)Tj
8 0 0 8 318 621.1616 Tm
[(Health Services Research, Baylor College of Medicine, Houston, )17.7 (T)69.9 (exas,)]TJ
0 Tw 0 -1.25 TD
(USA;)Tj
/T1_3 1 Tf
0.00729 Tw 10 0 0 10 318 599.1616 Tm
[(Patricia W)54.8 (o)-0.1 (o)]TJ
/T1_2 1 Tf
0 Tc 0 Tw [0.1 (, )]TJ
0.0249 Tw 6 0 0 6 379.1421 599.1616 Tm
(MD, PhD,)Tj
-0.00011 Tc 8 0 0 8 318 589.1616 Tm
(Pediatric Rheumatology Unit, University College London Medical)Tj
T*
(School, London, United Kingdom.)Tj
/T1_1 1 Tf
0 -2.75 TD
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. R.E. Petty)54.8 (, )17.7 (Ambulatory Car)36.8 (e Center K 4-)]TJ
0 -1.25 TD
[(121, British Columbia\325)128.8 (s Childr)36.8 (en\325)128.8 (s Hospital, 4480 Oak Str)36.8 (eet, V)110.7 (ancouver)110.7 (,)]TJ
T*
(British Columbia V6H 3V4, Canada.)Tj
/T1_3 1 Tf
0 Tw 10 0 0 10 318 513.1616 Tm
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 325 503.1616 Tm
[(1.)-875.1 (Petty RE, Southwood )17.7 (TR, Baum J, et al. Revision of the proposed)]TJ
1.675 -1.25 Td
(classification criteria for juvenile idiopathic arthritis: Durban, 1997.\
)Tj
T*
(J Rheumatol 1998;25:1991-4.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Bernston L, Fasth )54.8 (A, )54.8 (Andersson-G\212re B, et al. Construct validity of)]TJ
1.675 -1.25 Td
(ILAR and EULAR criteria in juvenile idiopathic arthritis; a )Tj
T*
(population based incidence study from the Nordic countries. )Tj
T*
(J Rheumatol 2001;28:2737-43.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Fantini F)79.7 (. Classification of chronic arthritides in childhood \(juvenile)]TJ
1.675 -1.25 Td
(idiopathic arthritis\): criticisms and suggestions to improve the )Tj
T*
[(ef)17.7 (ficacy of the Santiago-Durban criteria. J Rheumatol )]TJ
0 Tc 0 Tw T*
(2001;28:456-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Foeldvari I, Bidde M. )17.7 (V)110.8 (alidation of the proposed ILAR )]TJ
1.675 -1.25 Td
(classification criteria for juvenile idiopathic arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2000;27:1069-72.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Hayata )54.8 (ALS, Kochen JAL, Goldenstein-Schainber)17.7 (g C. Comparison)]TJ
1.675 -1.25 Td
[(of )54.8 (ACR, EULAR and ILAR \(Durban\) classification criteria for)]TJ
T*
(juvenile idiopathic arthritis \(JIA\) on a cohort of 154 Brazilian )Tj
T*
[(children [abstract]. )54.8 (Arthritis Rheum 2001;44 Suppl:S169.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Hofer MF)79.7 (, Mouy R, Prieur )54.8 (A-M. Juvenile idiopathic arthritides)]TJ
1.675 -1.25 Td
(evaluated prospectively in a single center according to the Durban)Tj
T*
(criteria. J Rheumatol 2000;28:1083-90.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Krumrey-Langkammerer M, Hafner R. Evaluation of the ILAR)]TJ
1.675 -1.25 Td
(criteria for juvenile idiopathic arthritis. J Rheumatol )Tj
0 Tc 0 Tw T*
(2002;28:2544-7.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Murray KJ, Moroldo MB, Donnelly P)110.7 (, et al. )54.8 (Age-specific ef)17.7 (fects of)]TJ
1.675 -1.25 Td
[(juvenile rheumatoid arthritis-associated HLA)-220.2 (alleles. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1999;42:1843-53.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Ramsay SE, Bolaria RK, Cabral DA, Malleson PN, Petty RE.)]TJ
1.675 -1.25 Td
(Comparison of criteria for the classification of childhood arthritis. )Tj
T*
(J Rheumatol 2000;27:1283-6.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Thomas E, Barrett JH, Donn R, )17.7 (Thomson )17.7 (W)91.9 (,)-0.1 ( Southwood )17.7 (TR, and)]TJ
2.175 -1.25 Td
(the British Paediatric Rheumatology Group. Subtyping of juvenile)Tj
T*
[(idiopathic arthritis using latent class analysis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;43:1496-503.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Thomson )17.7 (W)91.9 (, Barrett JH, Donn R, et al. Juvenile idiopathic arthritis)]TJ
2.1381 -1.25 Td
[(classified by the ILAR criteria: HLA)-220.2 (associations in UK patients.)]TJ
T*
[(Rheumatology Oxford 2002;41:1)36.8 (183-9.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 19, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\7!H,h0#ikq,j?(hm_*A&2C"c9/2*.:-NAK4\L,$I+4^W=[336K%!?/>*V21`D
"uZiIj0Mj4r?n0RF`f=6N?B>]3tW5G"j+D`F?G=f`L"*P0tkc"3Ata[Z,T[Gj?d.K
Ft-qR`nt4)#f>qQ%XNA'f4*G?`skpdZAMHnm9)N%$(X9rS:OqmX&M'JGC>8,>2%2E
logNX.dh;=CTXc(4ecb9eXp7R\BI]uXd=$m@jc"uf+M+aYBqa;;B:Qa_8@dL>*Hn/
=BplrDX((oB.VE+[;q452LE99DnHn(J$)ds'3I6ffC(/OYcD`UjX3IKH7''N;^qs
X6gR2&t-/k)0:tD_ONGe5dpOOL5uU"PCsHm=oX)LNi!SFQ4Kg]Rb'dKg1a/u[PW-'
E1u.W+Yid0(d,fY0PsHuQ*GkSf'PWhq2Ri.k8'-cia(p%U.O2?oo.)WB)l)!;jI~>
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
67 0 obj
<>
endobj
42 0 obj
<>
endobj
41 0 obj
<>
endobj
44 0 obj
<>
endobj
60 0 obj
<>
endobj
79 0 obj
<>
endobj
45 0 obj
<>
endobj
53 0 obj
<>stream
H\TPSg%bqdŪ<RQj5<,V$ Hry+uhv숶>ؕ.u{n3ӽ;gs;9H!"wA|Tdd̔DAkiҧOyK#~/.^FeW$%Q5 `Viszb$̐9S1uqǐ uD#:!ǜ5dnb5ڔju^^^5kmJ:Z`5)ZMSRձ:)#']XSfXN3g~d֥4Nk~f-"BxDHN{IDĢ`B)-dDDj"G9X^ ! JΓL%oՈ
{Nl9,~ᣆorZ,5rȃ#x{|*}}SpP R1|Q$XqR@.ajGÕ?R Rȩơ4
=lØ@%)2,bhV`XH|O|q[K9LsweMy1-Y~g)>n\6'ǘH̺:yaat%g[dG#-9EK ,/E*bZe9_a6@f 21x%kGxw0]rn`Z.O|GRTz_?@?tq aV 4_d-ve4KB#vz6Cȉ~0U1=80_=zKJ-xv-0
{nb8O'OvnKg*q*~
x`ȃQm(@8 hAB> tci WHZ,8 J22l7EE\Ob] 5k YѪR.4B}k!
Hʢ˝*x.[W0TC"7%o$eLv琪
l%sS2E*J{@'Ir@#.8TI=mo#PTI:
y|#C8xyrboz>s«c'`*^)|OC|;-n>czz